SEARCH

SEARCH BY CITATION

References

  • Calmy A, Pinoges L, Szumilin E et al. (2006) Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20, 11631169.
  • CASCADE Collaboration (2000) Survival after introduction of HAART in people with known duration of HIV-1 infection. The Lancet 355, 11581159.
  • Coetzee D, Hildebrand K, Boulle A et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18, 887895.
  • Detels R, Munoz A, McFarlane G et al. (1998) Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators The Journal of the American Medical Association 280, 14971503.
  • Farzadegan H, Hoover DR, Astemborski J et al. (1998) Sex differences in HIV-1 viral load and progression to AIDS. The Lancet 352, 15101514.
  • Ferradini L, Jeannin A, Pinoges L et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. The Lancet 367, 13351342.
  • Garcia de la Hera M, Ferreros I, Del Amo J et al. (2004) Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. Journal of Epidemiology and Community Health 58, 944950.
  • Garcia de Olalla P, Knobel H, Carmona A et al. (2002) Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 30, 105110.
  • Hogg RS, Yip B, Chan KJ et al. (2001) Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. The Journal of the American Medical Association 286, 25682577.
  • Iliyasu Z, Abubakar IS, Kabir M & Aliyu MH (2006) Knowledge of HIV/AIDS and attitude towards voluntary counseling and testing among adults. Journal of the National Medical Association 98, 19171922.
  • Lawn SD, Myer L, Harling G et al. (2006) Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clinical Infectious Diseases 43, 770776.
  • Libamba E, Makombe S, Harries AD et al. (2005) Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes – the case of Malawi. The International Journal of Tuberculosis and Lung Disease 9, 10621071.
  • Melnick SL, Sherer R, Louis TA et al. (1994) Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. The Journal of the American Medical Association 272, 19151921.
  • MoH Malawi (2005) HIV and Syphilis Sero-survey and National HIV Prevalence Estimates Report 2005. National AIDS Commission, Ministry of Health, Lilongwe.
  • MoH Malawi (2006) Treatment of AIDS. Guidelines for the Use of Antiretroviral Therapy in Malawi, 2nd edn. Ministry of Health, Lilongwe.
  • Moore AL, Sabin CA, Johnson MA & Phillips AN (2002) Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. Journal of Acquired Immune Deficiency Syndromes 29, 197202.
  • Napravnik S, Poole C, Thomas JC & Eron JJ Jr (2002) Gender difference in HIV RNA levels: a meta-analysis of published studies. Journal of Acquired Immune Deficiency Syndromes 31, 1119.
  • Nicastri E, Angeletti C, Palmisano L et al. (2005) Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 19, 577583.
  • Porter K, Babiker A, Bhaskaran K et al. (2003) Determinants of survival following HIV-1 seroconversion after the introduction of HAART. The Lancet 362, 12671274.
  • Prins M, Robertson JR, Brettle RP et al. (1999) Do gender differences in CD4 cell counts matter? AIDS 13, 23612364.
  • Stringer JSA, Zulu I, Levy J et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia – feasibility and early outcomes. The Journal of the American Medical Association 296, 782793.
  • Suligoi B (1997) The natural history of human immunodeficiency virus infection among women as compared with men. Sexually Transmitted Diseases 24, 7783.
  • Weidle PJ, Malamba S, Mwebaze R et al. (2002) Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients’ response, survival, and drug resistance. The Lancet 360, 3440.
  • Weiser SD, Heisler M, Leiter K et al. (2006) Routine HIV testing in Botswana: a population-based study on attitudes, practices, and human rights concerns. PLoS Medicine 3, e261.
  • Wester CW, Kim S, Bussmann H et al. (2005) Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. Journal of Acquired Immune Deficiency Syndromes 40, 336343.
  • WHO, UNAIDS & UNICEF (2007) Towards Universal Access. Scaling up Priority HIV/AIDS Interventions in the Health Sector. Progress report, April 2007. WHO, Geneva, Switzerland.
  • Wood E, Hogg RS, Yip B et al. (2006) Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or =200 cells/microl. AIDS 20, 11171123.
  • Wools-Kaloustian K, Kimaiyo S, Diero L et al. (2006) Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20, 4148.
  • Yu JKL, Chen SCC, Chang WS, Juma H & Chang CS (2005) Fingerprint identification of AIDS patients on ART. The Lancet 365, 1466.
  • Yu JKL, Chen SCC, Wang KY et al. (2007) True outcomes for patients on antiretroviral therapy who are “lost to follow-up” in Malawi. Bulletin of the World Health Organization 85, 550554.
  • Zachariah R, Fitzgerald M, Massaquoi M et al. (2006) Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 20, 23552360.